ArticleOncogene2026
Targeting of solute carrier family 1 member 1 that links metabolic reprogramming and ferroptosis sensitivity in pancreatic ductal adenocarcinoma.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solute carrier family 1 member 1 (SLC1A1, also known as excitatory amino acid transporter 3) is a member of the EAAT family of sodium-dependent glutamate carriers. Ferroptosis is a nonapoptotic cell death that is caused by phospholipid peroxidation promoted by radical reactions involving iron. Here, we identify SLC1A1 as a driver of ferroptosis resistance in PDAC cells and delineate the cause of its upregulation. SLC1A1 was overexpressed in PDAC tumors and correlated with poorer prognosis. Knockdown of SLC1A1 reduced cystine uptake by inhibiting glutamate transport, leading to decreased cysteine, GSH, and glutathione peroxidase 4 (GPX4) content, and the production of ROS and lipid peroxidation. Knockdown of SLC1A1 enhanced the ferroptosis sensitivity of PDAC cells and promoted ferroptosis inducer RSL3-induced ferroptosis and tumor suppression. Long noncoding RNA RASSF1-AS1 bound to CCCTC-binding factor (CTCF) protein, thereby inhibiting CTCF-mediated SLC1A1 transcription. Overexpression of RASSF1-AS1 enhanced the ferroptosis sensitivity of PDAC by blocking glutamate transport in vitro and in vivo, which was reversed by restoring CTCF/SLC1A1 signaling. Taken together, RASSF1-AS1 enhances the ferroptosis sensitivity of PDAC by inhibiting the CTCF/SLC1A1 axis-mediated intracellular transport of glutamate.
Indexed as
Identifiers
42432328What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.